Skip to main content
. Author manuscript; available in PMC: 2013 Jun 24.
Published in final edited form as: Int J Radiat Oncol Biol Phys. 2011 Apr 12;82(5):2018–2024. doi: 10.1016/j.ijrobp.2010.12.074

Fig. 1.

Fig. 1

Overall survival (A) and progression-free survival (B) from the time of salvage sterotactic radiosurgery (SRS) for patients with a recurrent World Health Organization Grade 4 glioma who did (+) or did not (−) receive adjuvant bevacizumab (BVZ).